GH, IGF1 and should I combine them ?

[western-biotech]

I've been asked more then several times if IGF1 should be combined with GH, and why not to take it by itself or instead of GH usage ? I posted this on my section as a source as well, and was adviced to post here as well to bring this to the attention of as many memers as possible.

In a nutshell the ideal solution is using GH in combination with IGF1-lr3 and/or IGF1-DES

It's true that the IGF1 is the mediator for most of the anabolic effect of the GH, but we must consider 2 things -

1. The GH has some direct metabolic effect by itself, both in releasing glucose and fatty acid into the circulation, and by this raising metabolism and releasing available energy for anabolic demands, The GH has also a direct effect on nitrogen balance not through the IGF1 path

2. The IGF1 itself has a direct suppressing effect on the endogenous GH release - so if u inject exogenous IGF you actually and directly suppress any GH present in the circulation

So the ideal solution is combining them both and by this keep optimal serum GH and IGF1 levels

 

[TSizemore]

Reading the title.....I expected a rather large discourse on this subject. Way to keep it succinct Western. Neat and Clean - I like it!

 

[western-biotech]

Here boss .... if need some back up there is a ton of clinical literature ... this one summarize it nicely

Format: AbstractSend to
JPEN J Parenter Enteral Nutr. 1999 Nov-Dec;23(6 Suppl):S184-9.
Effects of insulin-like growth factor-I and growth hormone in models of parenteral nutrition.
Ney DM1.
Author information
Abstract
BACKGROUND:
Administration of growth factors such as growth hormone (GH) and insulin-like growth factor-I (IGF-I) is being investigated as a strategy to promote nitrogen accretion in catabolic patients who may require total parenteral nutrition (TPN). IGF-I has advantages compared with GH because IGF-I enhances insulin sensitivity, is effective in conditions of GH resistance, and selectively stimulates the gastrointestinal and immune systems.
METHODS:
Experiments were conducted to evaluate the anabolic and metabolic effects associated with administration of recombinant human GH or IGF-I in rats subjected to clinically relevant stress and maintained with TPN.
RESULTS:
Administration of IGF-I, but not GH, attenuates dexamethasone-induced protein catabolism and increases insulin sensitivity. Simultaneous treatment with GH and IGF-I additively increases the serum concentration of IGF-I, whole-body anabolism, and lipid oxidation. GH or IGF-I when given alone produces similar increases in the serum concentration of IGF-I. However, GH selectively increases skeletal muscle mass whereas IGF-I selectively attenuates the intestinal atrophy and abnormal intestinal ion transport induced by TPN. These tissue-selective anabolic effects of GH and IGF-I are associated with differential increases in protein synthesis in skeletal muscle and jejunum, respectively.
CONCLUSIONS:
Simultaneous treatment with GH and IGF-I may offer the greatest clinical efficacy because of improved nitrogen retention in association with enhanced lipid oxidation and stimulation of protein synthesis in multiple tissue types.